Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Waxman

Showing results (101-110 of 632) with videos related to

Pageof 64
Sort By:
Molecular Cancer|December 31, 2010
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisKexiong Zhang, David J Waxman
The New England Journal of Medicine|November 12, 1987
Colchicine neuropathy or vitamin B12 deficiency neuropathy?J J Palopoli, J Waxman
Cancer Research|January 20, 2004
Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapyYoussef Jounaidi, David J Waxman
Anti-Cancer Drugs|January 1, 1996
Octreotide in malignant intestinal obstructionH S Pandha, J Waxman
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2013
DNase I digestion of isolated nulcei for genome-wide mapping of DNase hypersensitivity sites in chromatinGuoyu Ling, David J Waxman
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneEugene Manley, David J Waxman
Molecular Cancer Therapeutics|May 3, 2013
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor modelKexiong Zhang, David J Waxman
Molecular Pharmacology|April 19, 2002
Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stabilityDongxu Liu, David J Waxman
Cancer Gene Therapy|August 11, 2001
Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitorsZ Huang, D J Waxman
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistanceG Chen, D J Waxman
Pageof 64

Showing results (101-110 of 632) with videos related to

Sort By:
Pageof 64
Molecular Cancer|December 31, 2010
PC3 prostate tumor-initiating cells with molecular profile FAM65Bhigh/MFI2low/LEF1low increase tumor angiogenesisKexiong Zhang, David J Waxman
The New England Journal of Medicine|November 12, 1987
Colchicine neuropathy or vitamin B12 deficiency neuropathy?J J Palopoli, J Waxman
Cancer Research|January 20, 2004
Use of replication-conditional adenovirus as a helper system to enhance delivery of P450 prodrug-activation genes for cancer therapyYoussef Jounaidi, David J Waxman
Anti-Cancer Drugs|January 1, 1996
Octreotide in malignant intestinal obstructionH S Pandha, J Waxman
Methods in Molecular Biology (Clifton, N.J.)|February 26, 2013
DNase I digestion of isolated nulcei for genome-wide mapping of DNase hypersensitivity sites in chromatinGuoyu Ling, David J Waxman
The Journal of Pharmacology and Experimental Therapeutics|November 30, 2012
Impact of tumor blood flow modulation on tumor sensitivity to the bioreductive drug banoxantroneEugene Manley, David J Waxman
Molecular Cancer Therapeutics|May 3, 2013
Impact of tumor vascularity on responsiveness to antiangiogenesis in a prostate cancer stem cell-derived tumor modelKexiong Zhang, David J Waxman
Molecular Pharmacology|April 19, 2002
Post-transcriptional regulation of hepatic NADPH-cytochrome P450 reductase by thyroid hormone: independent effects on poly(A) tail length and mRNA stabilityDongxu Liu, David J Waxman
Cancer Gene Therapy|August 11, 2001
Modulation of cyclophosphamide-based cytochrome P450 gene therapy using liver P450 inhibitorsZ Huang, D J Waxman
The Journal of Pharmacology and Experimental Therapeutics|September 1, 1995
Complete reversal by thaliblastine of 490-fold adriamycin resistance in multidrug-resistant (MDR) human breast cancer cells. Evidence that multiple biochemical changes in MDR cells need not correspond to multiple functional determinants for drug resistanceG Chen, D J Waxman
Pageof 64